Ask about this productRelated genes to: PDE4B Blocking Peptide
- Gene:
- PDE4B NIH gene
- Name:
- phosphodiesterase 4B
- Previous symbol:
- DPDE4
- Synonyms:
- -
- Chromosome:
- 1p31.3
- Locus Type:
- gene with protein product
- Date approved:
- 1994-07-29
- Date modifiied:
- 2016-10-05
Related products to: PDE4B Blocking Peptide
Related articles to: PDE4B Blocking Peptide
- Acute lung injury (ALI) is a severe, potentially fatal condition associated with respiratory failure and high mortality, with limited effective therapeutic options. Rebamipide (REB), a gastroprotective agent with reported antioxidant and anti-inflammatory properties, has not been fully investigated in ALI. This study aimed to evaluate the effects and underlying mechanisms of REB in a lipopolysaccharide (LPS)-induced ALI rat model. Twenty-four Sprague-Dawley rats were randomly divided into four groups: control, REB (100 mg/kg orally for 10 days), LPS (5 mg/kg intraperitoneally on day 10), and REB + LPS (REB pretreatment for 10 days followed by LPS injection on day 10). REB administration attenuated LPS-induced pulmonary oxidative stress and inflammatory responses, as evidenced by reduced pro-inflammatory cytokines and improved antioxidant status. Additionally, REB modulated macrophage polarization markers and downregulated PDE4B expression. These changes were associated with increased cAMP, PKA, and p-CREB levels, along with inhibition of NF-κB p65 activation in lung tissue. In conclusion, REB exerts protective effects against LPS-induced ALI through modulation of inflammatory and oxidative stress pathways involving the PDE4B/cAMP/PKA/p-CREB axis and NF-κB signaling. These findings suggest that REB may represent a promising candidate for further investigation in inflammatory lung disorders. - Source: PubMed
Publication date: 2026/06/08
Kamel Gellan Alaa MohamedElzaitony Asmaa SHassan Abrar Gomaa Abd ElfattahMohammad Zahraa Zakarya Abd El-HafezIbrahim Amel BGomaa Asmaa A - Phosphodiesterases (PDEs) are considered promising drug targets due to their close association with various pathological and physiological processes. We aimed to investigate the causal relationship between PDE inhibitors and hypertensive disorders of pregnancy (HDP) and fetal growth restriction (FGR). - Source: PubMed
Publication date: 2026/05/20
Xia DandanLi SiyuLiu WenjieZhang YuhuiZhang ChenyingShe GuangtongWang Huiyan - Phosphodiesterase 4 (PDE4) is a validated target for chronic inflammatory diseases such as COPD, asthma, and psoriasis. Although four PDE4 inhibitors have received FDA approval (roflumilast, apremilast, crisaborole, and ensifentrine), all suffer dose-limiting gastrointestinal side effects due to insufficient PDE4B/PDE4D selectivity. Plant-derived natural products offer complementary chemical space for discovering inhibitors with novel binding modes and improved isoform selectivity. This review systematically surveys plant-derived PDE4 inhibitors reported from 1979 to 2024, spanning seven major scaffold classes: flavonoids (∼40%), terpenoids, coumarins, xanthones, benzofurans, fluorenones, and alkaloids. Structure-activity analyses reveal that hydroxylation patterns, C2C3 unsaturation, and B-ring substitution govern flavonoid potency. Structure-guided optimization of toddacoumalone ultimately yielded compound 33a (IC = 3.1 nM, PDE4D), the fluorenone selaginpulvilin K (IC = 11 nM, 30-909-fold family selectivity), and a semi-synthetic α-mangostin derivative (IC = 17 nM). Despite promising potencies, critical gaps persist in subtype selectivity profiling, pharmacokinetic characterization, and metabolic stability. We propose that integrating AI-guided optimization, structure-informed isoform-selective design, nanodelivery systems, and biotechnology-enhanced production can accelerate clinical translation of these scaffolds. - Source: PubMed
Publication date: 2026/05/19
Huang Hao - This study aimed to identify genomic regions and candidate genes associated with body composition, and meat quality traits in Iberian pigs fattened in Montanera. A genome-wide association study (GWAS) was conducted on 528 pigs for 29 phenotypic traits using genomic data from the GGP Porcine HD Array. After quality control, 526 animals and 35,894 SNPs were retained for the association analysis. Despite the limitations of the genotyping chip used, which lacked coverage for Iberian-specific variants, the GWAS performed with GCTA software identified 165 SNPs significantly associated with 11 traits. Among these, 145 SNPs were clustered into 25 quantitative trait loci (QTL) regions. Five QTLs were identified for ham yield, containing genes such as KCNIP4, ZNF438, and PID1. Eight QTLs were associated with loin yield, with genes like PREX2, RSPO1, and PDE4B. One QTL was associated with shear force, and 16 QTLs were related to fatty acid composition. Genes linked to these traits included ELOVL6, associated with myristic and palmitic acids, and ADCY9 and ROBO1, associated with linoleic acid. Overall, these results provide novel genomic insights and markers that could enhance selection strategies in Iberian pig breeding programs, while highlighting the need for improved genomic tools tailored to local breeds. - Source: PubMed
Publication date: 2026/05/16
Palma-Granados PatriciaGarcía-Casco Juan MRamón ManuelDelgado-Gutiérrez Miguel ASánchez-Esquiliche FernandoMárquez AlbertoMuñoz María - Hypersensitivity pneumonitis (HP) is characterized by bronchiolocentric inflammation and fibrosis. The characteristic pathological features include bronchiolocentric inflammation, peribronchiolar fibrosis, and the presence of poorly formed granulomas. Nerandomilast is a novel oral phosphodiesterase 4 (PDE4) inhibitor with good selectivity for PDE4B. PDE4 inhibitors (PDE4i) exhibit anti-inflammatory/antifibrotic properties, the efficacy of nerandomilast remains unexplored in HP. - Source: PubMed
Publication date: 2026/05/14
Shi YujieLiu YumingLiu ZhigangChen RuxuanWang MengqiLi ZhiyiChen QiShao ChiLi XiaoheZhou HonggangHuang Hui